What Happened With Bio-Path Stock Today?
What Happened With Bio-Path Stock Today?
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares closed slightly higher Wednesday after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.
bio-path holdings, Inc. (納斯達克：BPTH)股票週三略微上漲，公司發佈了BP1001-A在實體瘤患者中正在進行的Phase 10/10億臨床試驗的更新，並報告了BP1001在急性髓細胞白血病中進行的三聯組合研究的持續患者進展。
The Details: Bio-Path said the first patient treated with the higher dose in its Phase 1/1b study of BP1001-A has shown tumor regression and stable disease.
詳情：Bio-Path表示，在BP1001-A的Phase 10/10億研究中採用更高劑量治療的第一名患者顯示出腫瘤減退和穩定狀態。
"These positive responses mark a significant milestone for Bio-Path as they suggest our DNAbilize platform technology has the potential to produce multiple drug candidates capable of target-specific protein inhibition for over-expressed, disease-causing gene products," said Peter H. Nielsen, CEO of Bio-Path.
「這些積極的反應是Bio-Path的重要里程碑，表明我們的DNAbilize平台技術有可能產生多個能夠針對過度表達、引起疾病的基因產物進行特異性蛋白抑制的藥物候選劑，」Bio-Path的首席執行官彼得·H·尼爾森（Peter H. Nielsen）表示。
What Else: Bio-Path reported its second-quarter financial results last week and beat analyst expectations with GAAP losses of $1.16 per share.
另外：Bio-Path上週報告了其第二季度的財務業績，每股的估計損失低於分析師的預期1.16美元。
Research and development expenses decreased to $1.9 million primarily due to decreased manufacturing expenses and partially offset by an increase in expenses related to its clinical trial for BP1002 in lymphoma due to increased patient enrollment in 2024.
研發費用由於製造費用的減少和2024年增加患者招募導致BP1002在淋巴瘤臨床試驗中的費用增加，從而導致研發費用減少到190萬美元。
Bio-Path shares are moving lower in Wednesday's after-hours session.
Bio-Path股票在週三的盤後交易中走低。
BPTH Stock Prediction 2024: Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
BPTH股票預測2024：華爾街內外的股票研究分析師通常使用盈利增長和基本面研究作爲估值和預測的方式。但是，許多交易人會使用技術面分析來建立股票價格軌跡的預測模型。
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Bio-Path Holdings, an investor could make an assessment about a stock's long-term prospects using a moving average and trend line.
一些投資者通過趨勢來幫助預測股票在未來某一時點的交易情況。通過觀察Bio-Path Holdings，投資者可以利用移動平均線和趨勢線對股票的長期前景進行評估。
If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Bio-Path, the 200-day moving average sits at $5.55, according to Benzinga Pro, which is above the current price of $1.40. For more on charts and trend lines, see a description here.
如果他們相信股票將保持在移動平均線之上，許多人認爲這是一個看好的信號，他們可以利用趨勢線將該趨勢延伸到未來。對於bio-path holdings，根據Benzinga Pro的數據，200天的移動平均線位於5.55美元，高於當前的1.40美元。有關圖表和趨勢線的更多信息，請參閱這裏的說明。
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
交易員認爲，當股票位於其移動平均線上方時，這是一個普遍的看漲信號，當它跨越下方時，這是一個更消極的信號。如果條件保持穩定，投資者可以使用趨勢線來做出關於股票將在稍後時間交易的猜測。
BPTH Price Action: According to Benzinga Pro, Bio-Path Holdings shares are down 6.7% after-hours at $1.40 at the time of publication Wednesday.
Benzinga Pro稱，Bio-Path Holdings股票在週三發佈時下跌了6.7%，盤後交易價爲1.40美元。
- Read Also: What's Going On With Nano Nuclear Energy Stock?
- 閱讀更多：納米核能股票的最新動向是什麼？
Photo: Shutterstock
Photo: shutterstock
譯文內容由第三人軟體翻譯。